HomeCompareLXENF vs JNJ

LXENF vs JNJ: Dividend Comparison 2026

LXENF yields 400000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LXENF wins by $5.011119029548644e+32M in total portfolio value
10 years
LXENF
LXENF
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full LXENF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — LXENF vs JNJ

📍 LXENF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLXENFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LXENF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LXENF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LXENF
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, LXENF beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LXENF + JNJ for your $10,000?

LXENF: 50%JNJ: 50%
100% JNJ50/50100% LXENF
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

LXENF
No analyst data
Altman Z
-7.1
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LXENF buys
0
JNJ buys
0
No recent congressional trades found for LXENF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLXENFJNJ
Forward yield400000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$5.011119029548644e+32M$30.3K
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$5.010957816668433e+32M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LXENF vs JNJ ($10,000, DRIP)

YearLXENF PortfolioLXENF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$40,010,700$40,000,000.00$10,592$272.30+$40.00MLXENF
2$149,615,521,729$149,572,710,280.37$11,289$357.73+$149615.51MLXENF
3$522,880,052,725,200$522,719,964,116,949.25$12,123$472.89+$522880052.71MLXENF
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$13,141$629.86+$1707862989289.03MLXENF
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$14,408$846.81+$5213509402845684.00MLXENF
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$16,021$1,151.60+$14874219058409543680.00MLXENF
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$18,122$1,588.22+$3.966119623405075e+22MLXENF
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$20,930$2,228.20+$9.88384363503273e+25MLXENF
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$24,792$3,191.91+$2.302052364743449e+29MLXENF
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$30,274$4,689.40+$5.011119029548644e+32MLXENF

LXENF vs JNJ: Complete Analysis 2026

LXENFStock

Lithium Energi Exploration Inc. engages in the acquisition, exploration, and evaluating of lithium properties in Argentina. It holds interests in the Laguna Caro project that includes eight mining concessions covering approximately 17,759 hectares; the Antofalla North project that consists of thirteen mineral concessions covering approximately 41,496 hectares; and the Antofalla South project that includes eighteen mineral concessions covering 69,112 hectares in Argentina. The company was formerly known as Portola Resources Inc. and changed its name to Lithium Energi Exploration Inc. in March 2017. Lithium Energi Exploration Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.

Full LXENF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this LXENF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LXENF vs SCHDLXENF vs JEPILXENF vs OLXENF vs KOLXENF vs MAINLXENF vs ABBVLXENF vs MRKLXENF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.